Marshall Wace’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Marshall Wace’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-103,490	Closed	-$7.05M	–	3894
2022 Q3	$7.05M	Buy	103,490 +1,679	+2%	+$92.6K	0.02%	1137
2022 Q2	$3.25M	Buy	+101,811	New	+$2.98M	0.01%	1667
2022 Q1	–	Sell	-80,042	Closed	-$2.34M	–	4324
2021 Q4	$2.34M	Buy	80,042 +50,735	+173%	+$1.57M	﹤0.01%	1944
2021 Q3	$747K	Buy	+29,307	New	+$861K	﹤0.01%	2184
2020 Q4	–	Sell	-133,872	Closed	-$7.38M	–	2306
2020 Q3	$7.38M	Sell	133,872 -87,914	-40%	-$5.59M	0.05%	391
2020 Q2	$14M	Buy	+221,786	New	+$15.2M	0.1%	216
2017 Q1	–	Sell	-724,024	Closed	-$10.5M	–	835
2016 Q4	$10.5M	Buy	+724,024	New	+$12.7M	0.07%	322

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Marshall Wace's GBT Position: Q4 2022 in Review

Marshall Wace sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 103,490 shares — an estimated $7.05M sold.

Marshall Wace first reported a position in GBT in Q4 2016 and held it in 7 quarters. The position peaked at $14M in Q2 2020. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Marshall Wace reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Marshall Wace sold 103,490 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $7.05M.
Marshall Wace first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 7 quarters.
Marshall Wace's Global Blood Therapeutics, Inc. position peaked at $14M in Q2 2020.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.